Trials / Completed
CompletedNCT06851065
A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States
Luspatercept Treatment Patterns and Outcomes Among ESA-Naïve Patients With Lower-Risk MDS - A Retrospective Medical Record Review in the United States
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 418 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to understand real-world effectiveness of luspatercept treatment among erythropoiesis-stimulating agents -naïve patients with lower-risk- myelodysplastic syndromes in the United States
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Luspatercept | As per product lable |
| DRUG | Erythropoiesis-stimulating agents | As per product label |
Timeline
- Start date
- 2024-08-22
- Primary completion
- 2025-03-10
- Completion
- 2025-03-10
- First posted
- 2025-02-28
- Last updated
- 2026-02-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06851065. Inclusion in this directory is not an endorsement.